Caladrix
Biotechnology company (founded 2025) developing orally available small-molecule modulators of ATP-binding cassette (ABC) transporters to restore brain clearance mechanisms for Alzheimer’s disease and related neurodegenerative disorders. Operations include headquarters in Palo Alto, clinical operations in Melbourne, and R&D in Germany. Development strategy emphasizes non-immunologic, orally delivered disease-modifying therapies, translational biomarkers, and strategic partnerships with academic institutions and CROs.
Industries
N/A
Nr. of Employees
small (1-50)
Products
C-001 (oral ABC-transporter modulator) — lead clinical candidate
Orally available small-molecule modulator designed to enhance ABC-transporter-mediated clearance in early-stage Alzheimer’s disease; entering Phase 1 testing with planned Phase 2 follow-on studies. Additional candidates are in development for frontotemporal dementia and other tauopathies.
C-001 (oral ABC-transporter modulator) — lead clinical candidate
Orally available small-molecule modulator designed to enhance ABC-transporter-mediated clearance in early-stage Alzheimer’s disease; entering Phase 1 testing with planned Phase 2 follow-on studies. Additional candidates are in development for frontotemporal dementia and other tauopathies.
Services
Collaborative clinical development with academic centers and CROs for trial design, execution, and data generation.
On-the-ground clinical trial operations supporting patient enrollment and study conduct (noted presence in Melbourne for clinical trials).
Collaborative clinical development with academic centers and CROs for trial design, execution, and data generation.
On-the-ground clinical trial operations supporting patient enrollment and study conduct (noted presence in Melbourne for clinical trials).
Expertise Areas
- Neurodegenerative disease therapeutics (Alzheimer’s and tauopathies)
- Transporter-targeted small-molecule drug discovery
- Translational biomarker development and deployment
- Early-phase clinical trial design and execution (Phase 1/2)
Key Technologies
- ABC transporter modulation
- Small-molecule CNS drug delivery
- Modified-release oral formulation
- Plasma biomarker assays (pTau217, Aβ42/40, GFAP, NfL)
News & Updates
Randomized Phase 1 trial to evaluate safety, pharmacokinetics, and exploratory biomarker responses in ~90 patients with early Alzheimer’s disease using placebo, low-dose, and high-dose oral dosing.
Planned global Phase 2 pivotal study enrolling ~300 patients to assess disease-modifying potential using validated cognitive endpoints.
Announcement of an MSA with academic partners to advance the lead clinical candidate (C-001).
Attendance and presentations listed for industry conferences in 2025.
Company announcement framing the lead candidate as introducing a new non-immunologic class of Alzheimer’s therapy.
Randomized Phase 1 trial to evaluate safety, pharmacokinetics, and exploratory biomarker responses in ~90 patients with early Alzheimer’s disease using placebo, low-dose, and high-dose oral dosing.
Planned global Phase 2 pivotal study enrolling ~300 patients to assess disease-modifying potential using validated cognitive endpoints.
Announcement of an MSA with academic partners to advance the lead clinical candidate (C-001).
Attendance and presentations listed for industry conferences in 2025.
Company announcement framing the lead candidate as introducing a new non-immunologic class of Alzheimer’s therapy.